These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31880221)

  • 1. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
    Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
    J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL; Worley K; Meah Y; Everhart D
    J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.
    Cai J; Divino V; Burudpakdee C
    Curr Med Res Opin; 2017 Jul; 33(7):1317-1328. PubMed ID: 28418262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes.
    Hickson RP; Cole AL; Dusetzina SB
    J Manag Care Spec Pharm; 2019 Jan; 25(1):72-79. PubMed ID: 30589625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
    Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
    PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
    Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study.
    Nishimura R; Kato H; Kisanuki K; Oh A; Hiroi S; Onishi Y; Guelfucci F; Shimasaki Y
    BMJ Open; 2019 Mar; 9(3):e025806. PubMed ID: 30826768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographic Variation in Antidiabetic Agent Adherence and Glycemic Control Among Patients with Type 2 Diabetes.
    Tan E; Yang W; Pang B; Dai M; Loh FE; Hogan P
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1195-202. PubMed ID: 26679968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to dipeptidyl peptidase-4 inhibitor therapy among type 2 diabetes patients with employer-sponsored health insurance in Japan.
    Kurtyka K; Nishikino R; Ito C; Brodovicz K; Chen Y; Tunceli K
    J Diabetes Investig; 2016 Sep; 7(5):737-43. PubMed ID: 27182033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes.
    Ogundipe O; Mazidi M; Chin KL; Gor D; McGovern A; Sahle BW; Jermendy G; Korhonen MJ; Appiah B; Ademi Z; De Bruin ML; Liew D; Ofori-Asenso R
    Acta Diabetol; 2021 Jan; 58(1):39-46. PubMed ID: 32809070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
    Rathmann W; Kostev K; Gruenberger JB; Dworak M; Bader G; Giani G
    Diabetes Obes Metab; 2013 Jan; 15(1):55-61. PubMed ID: 22862879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
    Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
    PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
    King J; McAdam-Marx C; McCaleb R; Davis D; Bemberg GB; Johnson JT
    J Manag Care Spec Pharm; 2019 Jun; 25(6):646-651. PubMed ID: 31134855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.
    Garry EM; Schneeweiss S; Eapen S; Petruski-Ivleva N; Cheever E; Murk W; Rajan A; Rassen JA; Gambino D; Jang H; Rubin E; Jan S
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1442-1452. PubMed ID: 31778623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
    Mikhail N
    Postgrad Med; 2012 Jul; 124(4):138-44. PubMed ID: 22913902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
    Hong S; Han K; Park CY
    Mayo Clin Proc; 2020 Jan; 95(1):101-112. PubMed ID: 31812252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of medication adherence in patients with type 2 diabetes mellitus.
    Curkendall SM; Thomas N; Bell KF; Juneau PL; Weiss AJ
    Curr Med Res Opin; 2013 Oct; 29(10):1275-86. PubMed ID: 23815104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.